PPLPHARMA - PIRAMAL PHARMA LIMITED Share Price

Pharmaceuticals & Biotechnology

₹199.33-1.09(-0.54%)

Market Closed as of Nov 6, 2025, 15:30 IST

Select time range

Valuation
Market Cap	26.64 kCr
Price/Earnings (Trailing)	-1.11 K
Price/Sales (Trailing)	2.92
EV/EBITDA	22.64
Price/Free Cashflow	113.15
MarketCap/EBT	180.29
Enterprise Value	30.86 kCr

Fundamentals
Revenue (TTM)	9.11 kCr
Rev. Growth (Yr)	-8.4%
Earnings (TTM)	-23.74 Cr
Earnings Growth (Yr)	-539.2%

Profitability
Operating Margin	3%
EBT Margin	3%
Return on Equity	1.21%
Return on Assets	0.63%
Free Cashflow Yield	0.88%

Price to Sales Ratio

Latest reported: 3

Revenue (Last 12 mths)

Latest reported: 9 kCr

Net Income (Last 12 mths)

Latest reported: -24 Cr

Growth & Returns
Price Change 1W	-0.80%
Price Change 1M	1%
Price Change 6M	-2.7%
Price Change 1Y	-27.3%
3Y Cumulative Return	5.7%

Cash Flow & Liquidity
Cash Flow from Investing (TTM)	-477.46 Cr
Cash Flow from Operations (TTM)	892.3 Cr
Cash Flow from Financing (TTM)	-440.83 Cr
Cash & Equivalents	499.44 Cr
Free Cash Flow (TTM)	227.92 Cr
Free Cash Flow/Share (TTM)	1.71

Balance Sheet
Total Assets	16.19 kCr
Total Liabilities	8.12 kCr
Shareholder Equity	8.07 kCr
Current Assets	5.95 kCr
Current Liabilities	4.16 kCr
Net PPE	4.3 kCr
Inventory	2.74 kCr
Goodwill	1.19 kCr

Capital Structure & Leverage
Debt Ratio	0.3
Debt/Equity	0.58
Interest Coverage	-0.22
Interest/Cashflow Ops	3.23

Dividend & Shareholder Returns
Dividend/Share (TTM)	0.14
Dividend Yield	0.07%
Shares Dilution (1Y)	0.30%

Pros

Technicals: Bullish SharesGuru indicator.

Size: Market Cap wise it is among the top 20% companies of india.

Balance Sheet: Strong Balance Sheet.

Smart Money: Smart money has been increasing their position in the stock.

Buy Backs: Company has bought back it's stock in the past which is a good thing.

Cons

Momentum: Stock has a weak negative price momentum.

Past Returns: In past three years, the stock has provided 5.7% return compared to 13.5% by NIFTY 50.

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Rank

Balance Sheet

Momentum

Technicals

Smart Money

Insider Trading

Investor Care
Dividend Yield	0.07%
Dividend/Share (TTM)	0.14
Shares Dilution (1Y)	0.30%
Earnings/Share (TTM)	-0.18

Financial Health
Current Ratio	1.54
Debt/Equity	0.58

Technical Indicators
RSI (14d)	65.27
RSI (5d)	41.05
RSI (21d)	52.01
MACD Signal	Buy
Stochastic Oscillator Signal	Hold
Grufity Signal	Buy
RSI Signal	Hold
RSI5 Signal	Hold
RSI21 Signal	Hold
SMA 5 Signal	Sell
SMA 10 Signal	Sell
SMA 20 Signal	Buy
SMA 50 Signal	Buy
SMA 100 Signal	Buy

Summary of Latest Earnings Report from PIRAMAL PHARMA

Summary of PIRAMAL PHARMA's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.

Earnings Outlook

Last updated:

Q&A Session

Last updated:

Share Holdings

Understand PIRAMAL PHARMA ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.

Holding Pattern

Major Shareholders

Share Holding Details

Shareholder Name	Holding %
The Sri Krishna Trust through its Trustee Mr. Ajay G Piramal and Dr. (Mrs.) Swati A Piramal	26.55%
Ca Alchemy Investments	17.95%
Hdfc Trustee Company Limited-Hdfc Flexi Cap Fund	9.38%
V3 Designs LLP	3.24%
PRL Realtors LLP	2.99%
East Bridge Capital Master Fund I Ltd	2%
Indiahold Limited	1.3%
Canara Robeco Mutual Fund A/C Canara Robeco Small Cap Fund	1.1%
Piramal Welfare Trust	0.8%
Semplice Corporate Solutions Private Limited (Formerly known as AASAN Corporate Solutions Private Limited)	0.67%
The Ajay G. Piramal Foundation	0.33%
Mr. Anand Piramal	0.07%
Anand Piramal Trust	0.05%
Nandini Piramal Trust	0.04%
Mr. Ajay G. Piramal	0.04%
Mr. Peter DeYoung	0.03%
Ms. Nandini Piramal	0.02%
Ms. Anya Piramal DeYoung	0.01%
Master Dev Piramal DeYoung	0.01%
Alpex InfraConstructions Pvt. Ltd.	0%

Overall Distribution

Distribution across major stakeholders

Ownership Distribution

Distribution across major institutional holders

Is PIRAMAL PHARMA Better than it's peers?

Detailed comparison of PIRAMAL PHARMA against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.

Ticker	Name	Mkt Cap	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
SUNPHARMA	Sun Pharmaceutical Industries	4.06 LCr	56.98 kCr	+3.80%	-6.40%	38.82	7.13	-	-
DIVISLAB	Divi's Lab	1.81 LCr	10.04 kCr	+16.20%	+15.50%	78.53	18.02	-	-
CIPLA	Cipla	1.21 LCr	29.39 kCr	-0.90%	+2.60%	22.31	4.13	-	-
DRREDDY	Dr. Reddy's Lab	1 LCr	34.79 kCr	-3.80%	-5.30%	21.39	2.88	-	-
AUROPHARMA	Aurobindo Pharma	66.85 kCr	33.03 kCr	+5.30%	-18.20%	19.53	2.02	-	-

Sector Comparison: PPLPHARMA vs Pharmaceuticals & Biotechnology

Comprehensive comparison against sector averages

Comparative Metrics

PPLPHARMA metrics compared to Pharmaceuticals

Category	PPLPHARMA	Pharmaceuticals
PE	270.85	35.96
PS	2.86	5.06
Growth	9.1 %	7.5 %

Performance Comparison

PPLPHARMA vs Pharmaceuticals (2023 - 2025)

Key Insights

1. PPLPHARMA is NOT among the Top 10 largest companies in Pharmaceuticals.
2. The company holds a market share of 2.1% in Pharmaceuticals.
3. The company is growing at an average growth rate of other Pharmaceuticals companies.

Income Statement for PIRAMAL PHARMA

Consolidated figures (in Rs. Crores) / View Standalone Data

AnnualQuarterly

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023
Revenue From Operations	12%	9,151	8,171	7,082
Other Income	-23%	135	175	225
Total Income	11.3%	9,286	8,347	7,307
Cost of Materials	4%	2,056	1,977	1,682
Purchases of stock-in-trade	20.5%	1,417	1,176	952
Employee Expense	13.7%	2,307	2,030	1,896
Finance costs	-5.8%	422	448	344
Depreciation and Amortization	10.1%	816	741	677
Other expenses	8.8%	2,167	1,991	1,854
Total Expenses	9.6%	8,944	8,164	7,474
Profit Before exceptional items and Tax	87.4%	342	183	-167.52
Exceptional items before tax	98.4%	0	-62.79	-6.96
Total profit before tax	186.6%	342	120	-174.48
Current tax	67.9%	310	185	110
Deferred tax	148.2%	13	-23.88	-44.09
Total tax	101.9%	324	161	66
Total profit (loss) for period	429.4%	91	18	-186.46
Other comp. income net of taxes	41.1%	80	57	176
Total Comprehensive Income	129.7%	171	75	-10.66
Earnings Per Share, Basic	64%	0.69	0.14	-1.57
Earnings Per Share, Diluted	62.8%	0.68	0.14	-1.57

Description	(%) Q/Q	Sep-2025	Jun-2025	Mar-2025	Dec-2024	Sep-2024	Jun-2024
Revenue From Operations	5.7%	2,044	1,934	2,754	2,204	2,242	1,951
Other Income	14%	66	58	42	12	61	20
Total Income	5.9%	2,109	1,992	2,796	2,216	2,303	1,971
Cost of Materials	-7.8%	483	524	204	805	575	471
Purchases of stock-in-trade	9.4%	375	343	547	161	395	315
Employee Expense	-1.3%	611	619	612	556	560	580
Finance costs	-4.7%	82	86	104	103	108	107
Depreciation and Amortization	3.1%	203	197	243	197	192	185
Other expenses	11.1%	571	514	626	504	544	493
Total Expenses	2.8%	2,170	2,110	2,540	2,167	2,200	2,038
Profit Before exceptional items and Tax	48.1%	-60.97	-118.33	257	50	103	-67.48
Exceptional items before tax	-105%	0	21	0	0	0	0
Total profit before tax	37.1%	-60.97	-97.59	257	50	103	-67.48
Current tax	63.6%	55	34	94	72	94	50
Deferred tax	89.9%	-2.3	-31.54	25	-8.86	3.26	-6.5
Total tax	2995.2%	53	2.68	119	63	98	44
Total profit (loss) for period	-21.2%	-99.22	-81.7	154	3.68	23	-88.64
Other comp. income net of taxes	62.8%	71	44	14	15	55	-4.15
Total Comprehensive Income	24%	-28.31	-37.56	167	19	78	-92.79
Earnings Per Share, Basic	-8%	-0.75	-0.62	1.16	0.03	0.17	-0.67
Earnings Per Share, Diluted	-8%	-0.75	-0.62	1.16	0.03	0.17	-0.67

Standalone figures (in Rs. Crores) / View Consolidated Data

AnnualQuarterly

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023
Revenue From Operations	20.4%	5,286	4,390	3,443
Other Income	2.5%	207	202	341
Total Income	19.6%	5,493	4,592	3,784
Cost of Materials	3.3%	1,597	1,546	1,166
Purchases of stock-in-trade	17.5%	734	625	549
Employee Expense	19.9%	736	614	548
Finance costs	7.5%	115	107	116
Depreciation and Amortization	8.3%	222	205	192
Other expenses	20.4%	1,263	1,049	1,029
Total Expenses	12.2%	4,582	4,085	3,654
Profit Before exceptional items and Tax	79.5%	911	508	131
Exceptional items before tax	-	0	0	-6.96
Total profit before tax	79.5%	911	508	124
Current tax	78.4%	199	112	39
Deferred tax	550.7%	20	3.92	15
Total tax	90.4%	220	116	54
Total profit (loss) for period	76.9%	691	391	70
Other comp. income net of taxes	185.6%	5.5	-4.26	-18.35
Total Comprehensive Income	80.3%	697	387	51
Earnings Per Share, Basic	105.9%	5.22	3.05	0.58
Earnings Per Share, Diluted	104.9%	5.2	3.05	0.58
Debt equity ratio	-	-	-	031
Debt service coverage ratio	-	-	-	0.0102
Interest service coverage ratio	-	-	-	0.0213

Description	(%) Q/Q	Sep-2025	Jun-2025	Mar-2025	Dec-2024	Sep-2024	Jun-2024
Revenue From Operations	16.2%	1,127	970	1,690	1,248	1,284	1,063
Other Income	11.7%	202	181	40	25	106	37
Total Income	15.5%	1,329	1,151	1,729	1,273	1,391	1,100
Cost of Materials	-14.4%	351	410	337	474	380	406
Purchases of stock-in-trade	12.6%	216	192	150	174	233	176
Employee Expense	-6.5%	189	202	199	174	177	187
Finance costs	-13.6%	20	23	31	29	30	25
Depreciation and Amortization	3.4%	61	59	61	55	54	52
Other expenses	19.6%	355	297	351	324	313	275
Total Expenses	7.3%	1,082	1,008	1,365	1,114	1,115	988
Profit Before exceptional items and Tax	73.2%	247	143	364	159	276	112
Total profit before tax	73.2%	247	143	364	159	276	112
Current tax	68.4%	33	20	70	41	62	27
Deferred tax	104.3%	19	9.81	18	-0.22	4.02	-1.04
Total tax	78.6%	51	29	87	41	66	26
Total profit (loss) for period	74.1%	196	113	277	119	210	85
Other comp. income net of taxes	-666.3%	-27.43	-2.71	13	-3.53	-1.1	-3.3
Total Comprehensive Income	54.1%	169	110	291	115	209	82
Earnings Per Share, Basic	420%	1.48	0.85	2.09	0.9	1.59	0.64
Earnings Per Share, Diluted	413.3%	1.47	0.85	2.09	0.9	1.59	0.64
Debt equity ratio	-	-	-	-	-	-	-
Debt service coverage ratio	-	-	-	-	-	-	-
Interest service coverage ratio	-	-	-	-	-	-	-

Balance Sheet for PIRAMAL PHARMA

Consolidated figures (in Rs. Crores) / View Standalone Data

Description	(%) Q/Q	Sep-2025	Mar-2025	Sep-2024	Mar-2024	Sep-2023	Mar-2023
Cash and cash equivalents	35.3%	499	369	270	357	252	196
Current investments	1063.2%	222	20	10	145	59	427
Total current financial assets	-5.8%	2,757	2,926	2,280	2,778	2,409	2,626
Inventories	18.6%	2,743	2,313	2,447	2,176	2,060	1,681
Current tax assets	-18.5%	5.37	6.36	1.37	-	-	0
Total current assets	2.7%	5,953	5,797	5,382	5,464	4,954	4,835
Property, plant and equipment	3.1%	4,304	4,176	3,930	3,873	3,343	3,363
Capital work-in-progress	16%	567	489	621	566	989	853
Goodwill	3.5%	1,188	1,148	1,130	1,123	1,118	1,108
Non-current investments	0%	44	44	37	35	40	42
Total non-current financial assets	3.1%	67	65	59	56	65	289
Total non-current assets	3.6%	10,236	9,881	9,860	9,847	9,822	9,687
Total assets	3.3%	16,189	15,678	15,242	15,312	14,776	14,523
Borrowings, non-current	3.2%	3,317	3,214	1,535	2,484	2,861	3,384
Total non-current financial liabilities	3.1%	3,416	3,313	1,643	2,602	2,957	3,490
Provisions, non-current	85.4%	90	49	42	32	29	21
Total non-current liabilities	4.5%	3,956	3,786	2,097	3,031	3,421	3,906
Borrowings, current	-7.1%	1,399	1,506	3,108	2,075	1,543	2,121
Total current financial liabilities	4.6%	3,598	3,440	4,751	3,898	3,270	3,571
Provisions, current	-61.9%	17	43	51	44	44	39
Current tax liabilities	85.8%	17	9.61	8.55	40	19	3.54
Total current liabilities	10.5%	4,160	3,766	5,237	4,369	3,597	3,843
Total liabilities	7.5%	8,116	7,552	7,335	7,400	7,018	7,749
Equity share capital	0.2%	1,326	1,324	1,323	1,323	1,323	1,193
Total equity	-0.6%	8,074	8,125	7,907	7,911	7,758	6,774
Total equity and liabilities	3.3%	16,189	15,678	15,242	15,312	14,776	14,523

Standalone figures (in Rs. Crores) / View Consolidated Data

Description	(%) Q/Q	Sep-2025	Mar-2025	Sep-2024	Mar-2024	Sep-2023	Mar-2023
Cash and cash equivalents	49.1%	244	164	117	229	98	54
Current investments	-	211	0	0.01	61	45	100
Loans, current	8.3%	14	13	171	47	1.55	34
Total current financial assets	1.6%	1,970	1,939	1,482	1,730	1,252	1,133
Inventories	23.2%	1,484	1,205	1,352	1,153	1,042	819
Total current assets	5.7%	3,737	3,536	3,333	3,292	2,661	2,349
Property, plant and equipment	-0.3%	2,004	2,011	1,758	1,727	1,671	1,674
Capital work-in-progress	22.1%	95	78	254	232	155	136
Goodwill	0%	161	161	161	161	161	161
Non-current investments	7.4%	3,336	3,105	2,964	1,647	1,647	1,647
Loans, non-current	3.5%	473	457	494	1,395	950	971
Total non-current financial assets	7%	3,830	3,581	3,478	3,062	2,619	2,635
Total non-current assets	3.8%	7,118	6,856	6,690	6,259	5,697	5,694
Total assets	4.4%	10,854	10,392	10,023	9,551	8,358	8,042
Borrowings, non-current	48.6%	530	357	242	364	299	592
Total non-current financial liabilities	49.2%	553	371	257	382	315	615
Provisions, non-current	85.4%	90	49	42	32	29	21
Total non-current liabilities	38.4%	876	633	497	611	541	829
Borrowings, current	-59%	355	865	1,193	788	305	1,035
Total current financial liabilities	-12.8%	1,906	2,185	2,270	1,971	1,371	1,861
Provisions, current	-61.9%	17	43	51	44	44	39
Current tax liabilities	-	15	0	9.15	41	0	-
Total current liabilities	-3%	2,236	2,306	2,509	2,228	1,473	1,951
Total liabilities	5.9%	3,111	2,939	3,006	2,839	2,014	2,781
Equity share capital	0.2%	1,326	1,324	1,323	1,323	1,323	1,193
Total equity	3.9%	7,743	7,453	7,017	6,712	6,344	5,262
Total equity and liabilities	4.4%	10,854	10,392	10,023	9,551	8,358	8,042

Cash Flow for PIRAMAL PHARMA

Consolidated figures (in Rs. Crores) / View Standalone Data

Finance costs	-5.8%
Change in inventories	62.8%
Depreciation	10.1%
Unrealised forex losses/gains	-34%
Adjustments for interest income	-18.2%
Share-based payments	80.8%
Net Cashflows from Operations	5.3%
Income taxes paid (refund)	113.5%
Other inflows (outflows) of cash	79.2%
Net Cashflows From Operating Activities	-11.3%
Cash payment for investment in partnership firm or association of persons or LLP	-
Proceeds from sales of PPE	608.3%
Purchase of property, plant and equipment	-6.8%
Dividends received	114.3%
Other inflows (outflows) of cash	138.3%
Net Cashflows From Investing Activities	-10%
Proceeds from issuing shares	-100.1%
Payments to acquire or redeem entity's shares	-107.7%
Proceeds from borrowings	180.7%
Repayments of borrowings	75.2%
Payments of lease liabilities	50%
Dividends paid	-
Interest paid	-
Other inflows (outflows) of cash	99.8%
Net Cashflows from Financing Activities	-4.4%
Effect of exchange rate on cash eq.	-169.9%
Net change in cash and cash eq.	-123%

Standalone figures (in Rs. Crores) / View Consolidated Data

Finance costs	7.5%
Change in inventories	72.7%
Depreciation	8.3%
Unrealised forex losses/gains	658.4%
Dividend income	-104.3%
Adjustments for interest income	-101.6%
Share-based payments	89.7%
Net Cashflows from Operations	91.7%
Dividends received	-
Interest received	-
Income taxes paid (refund)	202.6%
Net Cashflows From Operating Activities	53.5%
Cashflows used in obtaining control of subsidiaries	-
Proceeds from sales of PPE	88.8%
Purchase of property, plant and equipment	-13.2%
Proceeds from sales of investment property	-
Dividends received	114.3%
Interest received	166.7%
Other inflows (outflows) of cash	687.7%
Net Cashflows From Investing Activities	13.4%
Proceeds from issuing shares	-99.8%
Proceeds from borrowings	-81.6%
Repayments of borrowings	-89.5%
Payments of lease liabilities	31.6%
Dividends paid	-
Interest paid	26%
Other inflows (outflows) of cash	93.4%
Net Cashflows from Financing Activities	-113.9%
Effect of exchange rate on cash eq.	-373%
Net change in cash and cash eq.	-137.9%

What does PIRAMAL PHARMA LIMITED do?

Pharmaceuticals•Healthcare•Small Cap

Piramal Pharma Limited operates as a pharmaceutical company in North America, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the spectrum of the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; complex hospital generics business which offers inhalation anesthetics, intrathecal therapy for spasticity management, injectable pain and anesthesia drugs, and other generic and specialty products; and India consumer healthcare business comprising analgesics, skin care, vitamin/mineral supplement, kids' wellness, digestives, women's health, and hygiene and protection. The company was incorporated in 2020 and is based in Mumbai, India.

Industry Group:Pharmaceuticals & Biotechnology

Employees:6,719

Website:www.piramalpharma.com

PPLPHARMA - PIRAMAL PHARMA LIMITED Share Price

Valuation

Fundamentals

Profitability

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

Growth & Returns

Cash Flow & Liquidity

Balance Sheet

Capital Structure & Leverage

Dividend & Shareholder Returns

Investor Care

Financial Health

Technical Indicators

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

What does PIRAMAL PHARMA LIMITED do?